Our approach for simultaneously targeting MMP-9 and IL-17A paves the way toward the development of bi-specific inhibitors targeting the MMPs and pro-inflammatory cytokines for the generation of novel cancer therapy agents [36, 39]. Here, IL17A is linked to cancer.